BCRX250117P17000
- 7.60
- 0.000.00%
BioCryst Pharmaceuticals Newsroom
BioCryst Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $12
BioCryst Pharma Analyst Ratings
Needham Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $15
Express News | BioCryst Pharmaceuticals Inc : Needham Raises Target Price to $15 From $14
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $18
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Announces Target Price $11
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $12
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $18
BioCryst Pharmaceuticals Sees FY25 Rev $540M-$560M >BCRX
Express News | BioCryst Pharmaceuticals: Expects to Approach Quarterly EPS Profitability/Positive Cash Flow in 2H 2025
Express News | BioCryst Pharmaceuticals: New Drug Application Planned in 2025 for Orladeyo Granules in Children up to Age 12
Express News | BioCryst Announces Preliminary Full Year 2024 Orladeyo® (Berotralstat) Net Revenue of $437 Million (+34 Percent Y-O-Y)
Express News | BioCryst Pharmaceuticals Q4 Product Sales USD 123.5 Million
BioCryst Announces Preliminary Full Year 2024 ORLADEYO (Berotralstat) Net Revenue of $437 Million (+34 Percent Y-o-y)
The 8.2% Return This Week Takes BioCryst Pharmaceuticals' (NASDAQ:BCRX) Shareholders Five-year Gains to 194%
Express News | BioCryst Pharmaceuticals Inc - Increases Wholesale Acquisition Cost for Orladeyo to $44,484.33 per 28-Day Pack
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
KalVista Pharmaceuticals' Sebetralstat Poised to Disrupt Acute HAE Market With Oral Advantage, BofA Says
KalVista Wins New Buy at BofA on Potential of Lead Candidate